Vestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in Q4, establishing a new stake. The purchase increased the fund's quarter-end position value by $181.80 million. This represents a sizable institutional entry that could be notable for Terns' stock trading and investor attention.
Vestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in Q4, establishing a new stake. The purchase increased the fund's quarter-end position value by $181.80 million. This represents a sizable institutional entry that could be notable for Terns' stock trading and investor attention.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
